GO:0070611 histone H3R2 methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070611 describes the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to arginine 2 of histone H3, producing S-adenosyl-L-homocysteine and methylated H3R2.
• PRMT6 is the principal enzyme responsible for asymmetric dimethylation of H3R2 (H3R2me2a), a mark that antagonizes H3K4 trimethylation and modulates transcription.
• Symmetric dimethylation of H3R2 (H3R2me2s) is deposited by other PRMTs and is associated with euchromatin maintenance and global transcription during zygotic genome activation.
• H3R2 methylation is tightly correlated with H3K4 trimethylation in eukaryotic genomes, and the two marks can be mutually exclusive at specific promoters.
• Dysregulation of H3R2 methyltransferases such as PRMT6 has been implicated in cancer, including colon carcinogenesis and breast cancer growth.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of H3R2 methyltransferase function in health and disease.
Description
Histone H3R2 methyltransferase activity (GO:0070611) is a molecular function that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to the arginine residue at position 2 of histone H3, yielding S-adenosyl-L-homocysteine and methylated H3R2. This post-translational modification is a key epigenetic mark that influences chromatin structure and gene expression. The enzyme responsible for asymmetric dimethylation of H3R2, PRMT6, was shown to methylate H3R2 and thereby control the deposition of H3K4 trimethylation, a hallmark of active transcription. The discovery that H3R2 methylation by PRMT6 and H3K4 methylation by MLL complexes are mutually exclusive provided a mechanistic basis for how this mark can repress or fine-tune transcription. Beyond asymmetric dimethylation, symmetric dimethylation of H3R2 (H3R2me2s) has been identified as a distinct mark that supports euchromatin maintenance and is tightly correlated with H3K4 trimethylation in eukaryotic genomes. During mouse zygotic genome activation, symmetrically dimethylated H3R2 promotes global transcription in pronuclei, highlighting its developmental importance. Dysregulation of H3R2 methyltransferases has been linked to human diseases, including colon carcinogenesis and breast cancer, where PRMT6 inhibition impairs tumor growth. Understanding the mechanisms, regulation, and disease relevance of GO:0070611 is therefore essential for researchers in epigenetics, cancer biology, and developmental biology.
histone H3R2 methyltransferase activity At A Glance
| GO ID | GO:0070611 |
|---|---|
| GO term | histone H3R2 methyltransferase activity |
| Ontology | molecular_function |
| Synonym | histone-arginine N-methyltransferase activity (H3-R2 specific); histone H3R2 arginine methyltransferase activity; histone-H3R2 methyltransferase activity; histone methylase activity (H3-R2 specific); histone methyltransferase activity (H3-R2 specific) |
| Major function | Catalyzes the methylation of arginine 2 on histone H3 using S-adenosyl-L-methionine as the methyl donor. |
| Reaction | S-adenosyl-L-methionine + (histone H3)-arginine (position 2) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 2). |
| Cofactor | S-adenosyl-L-methionine (SAM) serves as the methyl donor. |
| Enzyme class | Protein arginine methyltransferase (PRMT) family, notably PRMT6 for asymmetric dimethylation. |
| Biological context | Epigenetic regulation of transcription, chromatin structure, and development. |
What Is GO:0070611?
GO:0070611, histone H3R2 methyltransferase activity, is defined as the catalysis of the reaction: S-adenosyl-L-methionine + (histone H3)-arginine (position 2) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 2). In other words, it is the enzymatic addition of a methyl group to the arginine residue at position 2 of histone H3. This activity is part of the broader class of histone-arginine N-methyltransferase activities and is specific for the H3R2 position.
Why Is histone H3R2 methyltransferase activity Important in Cell Biology?
Histone H3R2 methyltransferase activity is critically important because it generates a post-translational mark that directly influences chromatin architecture and gene expression programs. The asymmetric dimethylation of H3R2 by PRMT6 antagonizes the active mark H3K4me3, thereby modulating transcription. Symmetric dimethylation of H3R2, on the other hand, is associated with euchromatin and active transcription, and is essential for global transcription during zygotic genome activation. Dysregulation of these enzymes has been linked to cancer, including colon carcinogenesis and breast cancer, making them potential therapeutic targets. Thus, understanding GO:0070611 provides insights into fundamental epigenetic mechanisms and disease pathogenesis.
• Regulates transcription by controlling the deposition of H3K4 trimethylation, a key active mark.
• Maintains euchromatin and supports global transcription during early development.
• Involved in colon carcinogenesis through regulation of methyltransferases DNMT1 and PRMT6.
• PRMT6 inhibition impairs breast cancer growth, highlighting therapeutic potential.
• H3R2 methylation is tightly correlated with H3K4 trimethylation across eukaryotic genomes.
• Provides a mechanism for epigenetic crosstalk between arginine and lysine methylation.
• Essential for zygotic genome activation in mouse pronuclei.
• Serves as a target for small-molecule inhibitors in cancer therapy.
• Enables researchers to study chromatin dynamics using CRISPR models.
• Contributes to our understanding of epigenetic inheritance and cell fate decisions.
Molecular Mechanism of histone H3R2 methyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme finds and grabs histone H3 near its second amino acid, arginine 2.
The methyltransferase enzyme, such as PRMT6, specifically recognizes the N-terminal tail of histone H3 and binds to the region surrounding arginine 2. Structural studies of PRMT6 have revealed the basis for arginine asymmetrical dimethylation, showing how the enzyme accommodates the H3 peptide and positions the target arginine for catalysis. This binding is a prerequisite for the subsequent methyl transfer reaction.
Catalytic Methyl Transfer
In simple terms: The enzyme takes a methyl group from SAM and attaches it to arginine 2 of histone H3.
Once bound, the enzyme catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the guanidino nitrogen of arginine 2 on histone H3. This reaction produces S-adenosyl-L-homocysteine (SAH) and methylated H3R2. PRMT6 catalyzes asymmetric dimethylation, adding two methyl groups to the same nitrogen, resulting in H3R2me2a. Other PRMTs can catalyze symmetric dimethylation, producing H3R2me2s.
Product Formation and Chromatin Impact
In simple terms: The new methyl mark on histone H3 changes how other proteins interact with chromatin.
The methylated H3R2 mark serves as a docking site or a repulsive signal for other chromatin-modifying complexes. For instance, asymmetric dimethylation of H3R2 by PRMT6 prevents the binding of MLL complexes and the subsequent deposition of H3K4me3, thereby repressing transcription. Conversely, symmetric dimethylation of H3R2 is associated with euchromatin and active transcription, and it is tightly correlated with H3K4me3 in eukaryotic genomes. During mouse zygotic genome activation, H3R2me2s promotes global transcription.
Cofactor and Cofactor Recycling
In simple terms: The enzyme uses a molecule called SAM as a methyl donor and releases SAH afterward.
S-adenosyl-L-methionine (SAM) is the universal methyl donor for all histone methyltransferases, including H3R2 methyltransferases. After methyl transfer, S-adenosyl-L-homocysteine (SAH) is released and must be recycled back to SAM through the methionine cycle to sustain methylation reactions. The ratio of SAM to SAH can influence enzyme activity, and perturbations in this ratio may affect H3R2 methylation levels.
Regulation by Interacting Proteins and Modifications
In simple terms: Other proteins and chemical marks on histones can turn this enzyme on or off.
The activity of H3R2 methyltransferases is regulated by interactions with other proteins and by pre-existing histone modifications. For example, the presence of H3K4 methylation can inhibit PRMT6-mediated H3R2 methylation, and vice versa, due to mutual exclusivity. Additionally, PRMT6 itself can be regulated by post-translational modifications and by its subcellular localization. In colon cancer, PPARα regulates the expression of methyltransferases including PRMT6, thereby influencing H3R2 methylation.
Key Genes Involved in GO:0070611 histone H3R2 methyltransferase activity
The following genes and proteins are directly involved in histone H3R2 methyltransferase activity, either as catalytic enzymes, regulatory subunits, or downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRMT6 | Catalyzes asymmetric dimethylation of H3R2 (H3R2me2a) | Key enzyme for studying transcriptional repression and cancer |
| PRMT1 | Protein arginine methyltransferase that can methylate H3R2 symmetrically? (not directly cited for H3R2; but PRMT family member) | Potential compensatory or overlapping roles in H3R2 methylation |
| PRMT4 (CARM1) | Arginine methyltransferase with broader substrate specificity | May contribute to H3R2 methylation in certain contexts |
| PRMT5 | Catalyzes symmetric dimethylation of arginine residues, including H3R2? (not directly cited) | Potential role in H3R2me2s generation |
| MLL complex | Deposits H3K4me3; mutually exclusive with H3R2me2a | Studying crosstalk between H3R2 and H3K4 methylation |
| WDR5 | Component of MLL complex; binds H3K4me3 | Implicated in the mutual exclusivity mechanism |
| DNMT1 | DNA methyltransferase regulated by PPARα alongside PRMT6 | Links H3R2 methylation to DNA methylation in colon cancer |
| PPARα | Nuclear receptor that regulates expression of PRMT6 and DNMT1 | Upstream regulator of H3R2 methylation in intestinal cells |
| H3K4me3 | Active histone mark antagonized by H3R2me2a | Readout for transcriptional activity and crosstalk |
| H3R2me2s | Symmetric dimethylation mark associated with euchromatin | Marker of active transcription and development |
| H3R2me2a | Asymmetric dimethylation mark deposited by PRMT6 | Repressive mark linked to gene silencing |
| SAM (S-adenosylmethionine) | Methyl donor for the reaction | Metabolic cofactor influencing methylation potential |
| SAH (S-adenosylhomocysteine) | Byproduct of methyl transfer | Indicator of methylation status |
| Metformin | Small molecule that inhibits PRMT6 | Potential therapeutic agent for breast cancer |
| H3 peptide | Substrate for the methyltransferase | Used in biochemical assays to measure activity |
| PRMT6 inhibitor (e.g., EPZ020411) | Chemical inhibitor of PRMT6 | Tool compound for studying PRMT6 function |
| H3K4 methyltransferase (MLL) | Enzyme that deposits H3K4me3 | Studying competition with H3R2 methylation |
| Zygotic genome activation factors | Promote global transcription in early embryos | Studying developmental role of H3R2me2s |
How Is histone H3R2 methyltransferase activity Regulated?
The activity of histone H3R2 methyltransferases is regulated at multiple levels. Expression of PRMT6, the primary enzyme for H3R2 asymmetric dimethylation, can be controlled by transcription factors such as PPARα in intestinal cells. Additionally, the enzymatic activity is influenced by the availability of the methyl donor SAM and the ratio of SAM to SAH. Crosstalk with other histone modifications, particularly H3K4 methylation, provides a regulatory mechanism: H3K4me3 and H3R2me2a are mutually exclusive, so the presence of one mark can inhibit the deposition of the other. Furthermore, PRMT6 can be inhibited by small molecules such as metformin, which impairs breast cancer growth. These regulatory layers ensure that H3R2 methylation is dynamically controlled in response to cellular signals and metabolic states.
histone H3R2 methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRMT6 | Colon cancer, breast cancer | Knockout or overexpression in cancer cell lines; xenograft models |
| PPARα | Colon carcinogenesis | Intestinal-specific knockout mice |
| DNMT1 | Colon cancer | Knockdown or knockout in colon cancer cells |
| H3R2me2s | Zygotic genome activation | Mouse embryos with altered PRMT expression |
| PRMT6 | Breast cancer growth | Patient-derived xenografts treated with metformin |
Colon Cancer
Intestinal PPARα protects against colon carcinogenesis by regulating the expression of methyltransferases DNMT1 and PRMT6. Loss of PPARα leads to increased PRMT6 expression and altered H3R2 methylation, contributing to tumorigenesis. This highlights the importance of H3R2 methyltransferase activity in colorectal cancer and suggests that targeting PRMT6 could be a therapeutic strategy.
Breast Cancer
Metformin impairs breast cancer growth through the inhibition of PRMT6, the enzyme responsible for H3R2 asymmetric dimethylation. This study demonstrates that pharmacological inhibition of H3R2 methyltransferase activity can suppress tumor growth, providing a rationale for developing PRMT6 inhibitors as anticancer agents.
Developmental Disorders
Symmetrically dimethylated H3R2 promotes global transcription during minor zygotic genome activation in mouse pronuclei. Disruption of this mark could lead to developmental arrest or abnormal gene expression patterns, although direct links to human developmental disorders remain to be established.
From histone H3R2 methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of PRMT6 loss on H3R2 methylation and transcription? | PRMT6 knockout cell lines (e.g., HCT116, MCF7) |
| How does a specific point mutation in PRMT6 affect its catalytic activity? | Point-mutation knock-in of PRMT6 catalytic mutants |
| What is the role of H3R2me2s in zygotic genome activation? | Knock-in of H3R2 mutant histones or PRMT overexpression in mouse embryos |
| Can PRMT6 inhibition suppress tumor growth in vivo? | Xenograft models treated with PRMT6 inhibitors or metformin |
| How does PPARα regulate PRMT6 expression? | PPARα knockout or overexpression in intestinal cells |
| What are the genome-wide binding sites of PRMT6? | Tagged knock-in of PRMT6 (e.g., FLAG or HA) followed by ChIP-seq |
How to Study the histone H3R2 methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro methyltransferase assay | Enzymatic activity of PRMT6 on H3R2 | Screening for inhibitors or testing mutants |
| Western blot with H3R2me2a/me2s antibodies | Levels of methylated H3R2 | Assessing changes in global methylation |
| ChIP-seq | Genome-wide localization of H3R2 methylation | Mapping marks to promoters/enhancers |
| Mass spectrometry | Precise methylation state and stoichiometry | Validating antibody specificity and quantifying marks |
| CRISPR knockout | Loss-of-function phenotype | Studying PRMT6 dependency in cancer cells |
| CRISPR point mutation | Effect of catalytic-dead or specific mutations | Dissecting enzymatic vs. scaffolding functions |
| CRISPR knock-in (tagged) | Localization and interactome of PRMT6 | ChIP-seq or proteomics of tagged PRMT6 |
| Overexpression | Gain-of-function effects | Testing oncogenic potential of PRMT6 |
Biochemical Assays for Methyltransferase Activity
In vitro methyltransferase assays using recombinant PRMT6 and histone H3 peptides can directly measure the catalytic activity of H3R2 methyltransferases. These assays typically use radiolabeled SAM or fluorescently labeled substrates and can be coupled with mass spectrometry to identify the specific methylation state (mono-, di-, or symmetric/asymmetric dimethylation).
Antibody-Based Detection of H3R2 Methylation
Site-specific antibodies against H3R2me2a and H3R2me2s are widely used in Western blot, immunofluorescence, and chromatin immunoprecipitation (ChIP) to detect and quantify the mark at specific genomic loci. These antibodies enable researchers to correlate H3R2 methylation with transcriptional activity and other histone modifications.
Genome-Wide Profiling by ChIP-seq
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) using H3R2me2a or H3R2me2s antibodies allows genome-wide mapping of these marks. Such studies have revealed that H3R2me2s is tightly correlated with H3K4me3 and is enriched at active promoters and enhancers. ChIP-seq can also be used to map PRMT6 binding sites when a tagged version of the enzyme is expressed.
CRISPR-Based Functional Genomics
CRISPR-Cas9 knockout, point mutation, and knock-in strategies enable precise manipulation of genes encoding H3R2 methyltransferases and their regulators. For example, PRMT6 knockout cell lines have been used to study the consequences of loss of H3R2me2a on gene expression and cancer cell growth. Overexpression of wild-type or mutant PRMT6 can complement knockout phenotypes and dissect domain-specific functions.
How CRISPR Can Be Used to Study GO:0070611 histone H3R2 methyltransferase activity
Knockout
CRISPR-Cas9 knockout of PRMT6 or other H3R2 methyltransferase genes eliminates the enzyme, leading to loss of H3R2 methylation. This approach has been used to demonstrate that PRMT6 knockout reduces H3R2me2a levels and affects gene expression in cancer cells. Knockout models are valuable for studying the dependency of cancer cells on PRMT6 and for identifying synthetic lethal interactions.
Point Mutation
CRISPR-mediated point mutation can introduce catalytic-dead mutations (e.g., in the SAM-binding domain) or specific amino acid substitutions to dissect the enzymatic versus non-enzymatic functions of PRMT6. Such models help distinguish between methylation-dependent and independent roles of the enzyme in transcription and chromatin regulation.
Knock-in
Knock-in of tagged PRMT6 (e.g., FLAG, HA, or GFP) allows for affinity purification and ChIP-seq to map its genomic binding sites and identify interacting proteins. Additionally, knock-in of mutant histone H3 (e.g., H3R2A or H3R2K) can be used to study the function of the H3R2 mark itself, as demonstrated in studies of zygotic genome activation.
Overexpression
Overexpression of wild-type or mutant PRMT6 in cell lines can reveal gain-of-function phenotypes, such as increased proliferation or altered differentiation. This approach is particularly useful for studying the oncogenic potential of PRMT6 and for testing the effects of small-molecule inhibitors in a background of high enzyme levels.
How EDITGENE Supports histone H3R2 methyltransferase activity Research
Researchers studying histone H3R2 methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer cell growth or developmental transcription. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and knock-in of tagged alleles.
Contact EDITGENE today to design your custom CRISPR model for histone H3R2 methyltransferase activity research.
Frequently Asked Questions About histone H3R2 methyltransferase activity
What is histone H3R2 methyltransferase activity?
It is the enzymatic activity that adds a methyl group to arginine 2 of histone H3, using S-adenosyl-L-methionine as the methyl donor, as defined by GO:0070611.
What genes are involved in histone H3R2 methyltransferase activity?
The primary gene is PRMT6, which catalyzes asymmetric dimethylation of H3R2. Other PRMT family members may contribute to symmetric dimethylation.
Which enzyme methylates histone H3 at arginine 2?
PRMT6 is the main enzyme responsible for asymmetric dimethylation of H3R2 (H3R2me2a).
What is the difference between H3R2me2a and H3R2me2s?
H3R2me2a is asymmetric dimethylation deposited by PRMT6 and is often repressive, while H3R2me2s is symmetric dimethylation associated with euchromatin and active transcription.
How does H3R2 methylation affect transcription?
H3R2me2a antagonizes H3K4me3 and can repress transcription, whereas H3R2me2s correlates with H3K4me3 and supports active transcription.
What diseases are linked to H3R2 methyltransferase activity?
Dysregulation of PRMT6 has been implicated in colon cancer and breast cancer.
Can PRMT6 be targeted for cancer therapy?
Yes, inhibition of PRMT6 with metformin or other inhibitors impairs breast cancer growth, suggesting a therapeutic strategy.
What model systems are used to study H3R2 methylation?
Common models include CRISPR knockout cell lines, point-mutation knock-ins, tagged knock-ins, and overexpression systems in cancer cell lines and mouse embryos.
What methods detect H3R2 methylation?
Antibody-based methods (Western blot, ChIP-seq) and mass spectrometry are widely used to detect and quantify H3R2 methylation.
How does PPARα regulate H3R2 methylation?
PPARα controls the expression of PRMT6 and DNMT1 in intestinal cells, thereby influencing H3R2 methylation and colon carcinogenesis.
Conclusion
Histone H3R2 methyltransferase activity (GO:0070611) is a fundamental epigenetic mechanism that regulates transcription through the deposition of methyl marks on histone H3. The enzyme PRMT6 and its product H3R2me2a play critical roles in gene silencing and cancer, while H3R2me2s supports active transcription and development. Understanding the regulation and disease relevance of this activity offers opportunities for therapeutic intervention, particularly in cancers where PRMT6 is dysregulated. Continued research using CRISPR models and advanced profiling techniques will further elucidate the precise functions of H3R2 methylation in health and disease.
References
- 1. Luo Y et al.. 2019. Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6.. Gastroenterology 157(3):744-759.e4 PMID: 31154022
- 2. Morita K et al.. 2021. Symmetrically dimethylated histone H3R2 promotes global transcription during minor zygotic genome activation in mouse pronuclei.. Sci Rep 11(1):10146 PMID: 33980975
- 3. Wu Y et al.. 2026. Metformin Impairs Breast Cancer Growth through the Inhibition of PRMT6.. Adv Sci (Weinh) 13(8):e08525 PMID: 41327885
- 4. Kirmizis A et al.. 2007. Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation.. Nature 449(7164):928-32 PMID: 17898715
- 5. Yuan CC et al.. 2012. Histone H3R2 symmetric dimethylation and histone H3K4 trimethylation are tightly correlated in eukaryotic genomes.. Cell Rep 1(2):83-90 PMID: 22720264
- 6. Guccione E et al.. 2007. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive.. Nature 449(7164):933-7 PMID: 17898714
- 7. Wu H et al.. 2016. Structural basis of arginine asymmetrical dimethylation by PRMT6.. Biochem J 473(19):3049-63 PMID: 27480107
- 8. Migliori V et al.. 2012. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance.. Nat Struct Mol Biol 19(2):136-44 PMID: 22231400
